Article Text

Download PDFPDF
Omalizumab reduced inhaled corticosteroid use and exacerbations in childhood allergic asthma

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 QUESTION: In children with moderate to severe allergic asthma who require daily inhaled corticosteroid (ICS) treatment, is omalizumab (anti-immunoglobulin E [anti-IgE] antibody) more effective than placebo for reducing steroid use and asthma exacerbations?


Randomised {allocation concealed*}, blinded (clinicians, patients {outcome assessors, and statisticians}†,)* placebo controlled trial with 34 weeks of follow up.


Research centres in 12 US states and in Washington, DC.


334 asthmatic patients who were 6 to 12 years of age (mean age 9 y, 69% boys) and whose asthma was well controlled with ICSs (beclomethasone dipropionate [BDP] and bronchodilator treatment) for ≥ 3 months before randomisation. Other inclusion criteria were allergic asthma for ≥ 1 year; positive skin prick test result to ≥ 1 of house dust mite, cockroach, dog, or cat; total serum IgE level between 30 …

View Full Text


  • Sources of funding: Genentech, Inc. and Novartis Pharmaceuticals Corporation.

  • For correspondence: Dr H Milgrom, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206, USA. milgromh{at}

  • * See glossary.

  • Information provided by author.